Current Report Filing (8-k)
November 20 2020 - 9:12AM
Edgar (US Regulatory)
0001513856
false
false
0001513856
2020-11-20
2020-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 20, 2020
NEUROTROPE, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
001-38045
|
46-3522381
|
(State or other
jurisdiction of
incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification
Number)
|
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
(Address of principal executive offices, including ZIP code)
(973) 242-0005
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
x
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
NTRP
|
|
The Nasdaq Stock Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On November 20, 2020,
Neurotrope, Inc. (the “Company”) announced that the Company’s Board of Directors approved the conditional distribution
in connection with the previously announced spin-off (the “Spin-Off”) of its wholly-owned subsidiary, Neurotrope Bioscience,
Inc. and set November 30, 2020 as the shareholder of record date and December 7, 2020 as the anticipated distribution date for
the Spin-Off. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
NEUROTROPE, INC.
|
|
|
|
|
|
Dated: November 20, 2020
|
By:
|
/s/ Robert Weinstein
|
|
|
|
Name: Robert Weinstein
|
|
|
|
Title: Chief Financial Officer, Executive Vice President, Secretary and Treasurer
|
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Oct 2024 to Nov 2024
NextTrip (NASDAQ:NTRP)
Historical Stock Chart
From Nov 2023 to Nov 2024
